{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-016981","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2026-05-14T18:00:13+00:00","discovered_at":"2026-05-14T18:01:23.512591+00:00","generated_at":"2026-05-14T18:02:20.893276+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar Therapeutics Q1 2026 net loss $3.9M; NDA on track for mid-2026","bullets":["Net loss $3.9M ($0.46/share) in Q1 2026 vs $2.6M ($0.38/share) in Q1 2025.","Cash equivalents and investments $137.5M; expects funding through Dec 2027.","NDA for ALXN1840 (Wilson disease) on track for FDA submission in mid-2026.","R&D expenses $3.49M, up $1.84M YoY due to contractor/consulting and personnel.","Presented at AAN; upcoming at EAN (June 27-30) and EASL Congress (May 27-30)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016981","json":"https://secwatch.observer/filing/0001437749-26-016981.json","markdown":"https://secwatch.observer/filing/0001437749-26-016981.md","text":"https://secwatch.observer/filing/0001437749-26-016981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/0001437749-26-016981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774926016981/mnpr20260513c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T18:02:20.893276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}